Department of Public Health, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, P.O. Box 96, Dschang, Cameroon.
Aix-Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Service de Santé des Armées (SSA), Unité Mixte de Recherche Vecteurs-Infections Tropicales et Méditerranéennes (VITROME), Marseille, France.
Malar J. 2021 May 21;20(1):228. doi: 10.1186/s12936-021-03768-1.
Several anti-malarial drugs have been evaluated in randomized clinical trials to treat acute uncomplicated Plasmodium falciparum malaria. The outcome of anti-malarial drug efficacy studies is classified into one of four possible outcomes defined by the World Health Organization: adequate clinical and parasitological response, late parasitological failure, late clinical failure, early treatment failure. These four ordered categories are ordinal data, which are reduced to either a binary outcome (i.e., treatment success and treatment failure) to calculate the proportions of treatment failure or to time-to-event outcome for Kaplan-Meier survival analysis. The arbitrary transition from 4-level ordered categories to 2-level type categories results in a loss of statistical power. In the opinion of the authors, this outcome can be considered as ordinal at a fixed endpoint or at longitudinal endpoints. Alternative statistical methods can be applied to 4-level ordinal categories of therapeutic response to optimize data exploitation. Furthermore, network meta-analysis is useful not only for direct comparison of drugs which were evaluated together in a randomized design, but also for indirect comparison of different artemisinin-based combinations across different clinical studies using a common drug comparator, with the aim to determine the ranking order of drug efficacy. Previous works conducted in Cameroonian children served as data source to illustrate the feasibility of these novel statistical approaches. Data analysis based on ordinal end-point may be helpful to gain further insight into anti-malarial drug efficacy.
几种抗疟药物已在随机临床试验中进行评估,以治疗急性无并发症恶性疟原虫疟疾。抗疟药物疗效研究的结果分为世界卫生组织定义的四种可能结果之一:充分的临床和寄生虫学反应、晚期寄生虫学失败、晚期临床失败、早期治疗失败。这四个有序类别是有序数据,可以简化为二分类结果(即治疗成功和治疗失败),以计算治疗失败的比例,或者为 Kaplan-Meier 生存分析计算时间事件结果。从 4 级有序类别到 2 级类型类别的任意转换会导致统计能力的损失。作者认为,这种结果可以在固定终点或纵向终点被视为有序。可以应用替代的统计方法对治疗反应的 4 级有序类别进行分析,以优化数据利用。此外,网络荟萃分析不仅可用于评估在随机设计中一起评估的药物之间的直接比较,还可用于使用共同药物比较剂对不同临床研究中的不同基于青蒿素的联合用药进行间接比较,以确定药物疗效的排序。先前在喀麦隆儿童中进行的研究作为数据来源,说明了这些新统计方法的可行性。基于有序终点的数据分析可能有助于更深入地了解抗疟药物的疗效。